FDA: J&J’s Ditropan Labeling Should Be Strengthened To Advise Of Hallucinations
This article was originally published in The Pink Sheet Daily
Documents issued ahead of a Pediatric Advisory Committee meeting April 11 urge stronger caution due to CNS effects of oxybutynin.
You may also be interested in...
Impax/Teva launching 15 mg strength, and Mylan joins with "authorized" generic as well as its own version of the 5 mg and 10 mg strengths.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.